MSN announced on August 14, 2026, that it has received final approval for ANDA 218873, opening the door to generic competition for the previously cited substance that will likely pressure brand pricing and expand market availability. Following the FDA clearance, the company is poised to significantly intensify competitive dynamics in the therapeutic class, potentially capturing a substantial share of the market and challenging legacy manufacturers with cost-effective alternatives.